The most common form of dementia, Alzheimer’s disease, is a progressive, neurodegenerative, non-reversible disorder inflicting an increasing number of people over the world. Numerous new therapies are being introduced in the global market for Alzheimer’s disease therapeutics, transforming the dynamics of the market. The findings of the Alzheimer’s Association reveal that over 5.5 million Americans are suffering from Alzheimer’s in 2017. According to Alzheimer’s Disease International, over three quarters of people with dementia have not yet received a formal diagnosis. These unmet needs of the global population, along with an alarming rise in the incidence of this disease in Asia, is expected to offer massive growth opportunities.
The wide assortment of reports on Alzheimer’s disease at ResearchMoz acknowledges the varied needs of the customers. The key catalysts, deterrents, and developments in the Alzheimer’s disease therapeutics market have been analyzed. A detailed evaluation of the competitive landscape, where the common business strategies of the major market players have been discussed is also included in these reports.